Loading...
XNYS
BDX
Market cap54bUSD
Jul 09, Last price  
150.85USD
1D
0.19%
1Q
-2.19%
Jan 2017
18.80%
Name

Becton Dickinson and Co

Chart & Performance

D1W1MN
XNYS:BDX chart
P/E
32.57
P/S
2.50
EPS
4.63
Div Yield, %
2.76%
Shrs. gr., 5y
0.33%
Rev. gr., 5y
6.32%
Revenues
21.84b
+8.23%
5,738,017,0006,359,708,0007,074,942,0006,986,722,0007,124,385,0007,584,000,0007,708,000,0008,054,000,0008,446,000,00010,282,000,00012,483,000,00012,093,000,00015,983,000,00017,290,000,00016,074,000,00019,131,000,00018,870,000,00019,372,000,00020,178,000,00021,839,000,000
Net income
1.68b
-1.58%
752,280,000890,033,0001,126,996,0001,231,603,0001,317,610,0001,271,000,0001,170,000,0001,293,000,0001,185,000,000695,000,000976,000,0001,100,000,000311,000,0001,233,000,000874,000,0002,092,000,0001,779,000,0001,484,000,0001,705,000,0001,678,000,000
CFO
3.43b
-9.69%
1,076,400,0001,240,436,0001,687,099,0001,716,816,0001,744,268,0001,716,000,0001,760,228,0001,507,000,0001,744,000,0001,729,000,0002,559,000,0002,550,000,0002,865,000,0003,330,000,0003,539,000,0004,647,000,0002,633,000,0002,989,000,0003,798,000,0003,430,000,000
Dividend
Dec 08, 20251.05 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Becton, Dickinson and Company (BD) is a global medical technology enterprise engaged in the development, manufacture, and distribution of a comprehensive range of medical supplies, advanced devices, laboratory equipment, and diagnostic products. Its vast product portfolio caters to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. The company operates through distinct segments. The BD Medical segment supplies a wide array of products including various peripheral and central intravenous (IV) catheters, vascular care and preparation solutions, needle-free IV connectors, and closed-system drug transfer devices. It also provides hypodermic, anesthesia, and enteral syringes and needles, sharps disposal systems, and prefillable drug delivery solutions. Additionally, this segment offers comprehensive medication management systems, covering IV medication and infusion therapy delivery, compounding workflow, automated dispensing, supply management, and inventory optimization, alongside syringes and pen needles specifically for diabetes care. The BD Life Sciences segment offers diagnostic and research tools, including specimen and blood collection products. Its offerings span automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology, in addition to rapid diagnostic assays, microbiology laboratory automation products, and plated media. For cell analysis, it provides fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. BD Interventional focuses on surgical and interventional solutions, featuring products for hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and various other surgical applications. This segment also includes items for surgical infection prevention, surgical and laparoscopic instrumentation, peripheral intervention, and specialized urology and critical care products. Founded in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
IPO date
Sep 25, 1963
Employees
77,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT